1. Home
  2. PTY vs WVE Comparison

PTY vs WVE Comparison

Compare PTY & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTY
  • WVE
  • Stock Information
  • Founded
  • PTY 2002
  • WVE 2012
  • Country
  • PTY United States
  • WVE Singapore
  • Employees
  • PTY N/A
  • WVE N/A
  • Industry
  • PTY Investment Managers
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTY Finance
  • WVE Health Care
  • Exchange
  • PTY Nasdaq
  • WVE Nasdaq
  • Market Cap
  • PTY 2.3B
  • WVE 2.1B
  • IPO Year
  • PTY N/A
  • WVE 2015
  • Fundamental
  • Price
  • PTY $14.32
  • WVE $13.51
  • Analyst Decision
  • PTY
  • WVE Strong Buy
  • Analyst Count
  • PTY 0
  • WVE 10
  • Target Price
  • PTY N/A
  • WVE $21.60
  • AVG Volume (30 Days)
  • PTY 550.4K
  • WVE 1.1M
  • Earning Date
  • PTY 01-01-0001
  • WVE 11-12-2024
  • Dividend Yield
  • PTY 9.65%
  • WVE N/A
  • EPS Growth
  • PTY N/A
  • WVE N/A
  • EPS
  • PTY N/A
  • WVE N/A
  • Revenue
  • PTY N/A
  • WVE $53,610,000.00
  • Revenue This Year
  • PTY N/A
  • WVE N/A
  • Revenue Next Year
  • PTY N/A
  • WVE $48.58
  • P/E Ratio
  • PTY N/A
  • WVE N/A
  • Revenue Growth
  • PTY N/A
  • WVE N/A
  • 52 Week Low
  • PTY $11.92
  • WVE $3.50
  • 52 Week High
  • PTY $14.88
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • PTY 27.61
  • WVE 45.88
  • Support Level
  • PTY $14.51
  • WVE $12.84
  • Resistance Level
  • PTY $14.85
  • WVE $14.57
  • Average True Range (ATR)
  • PTY 0.11
  • WVE 0.97
  • MACD
  • PTY -0.06
  • WVE -0.24
  • Stochastic Oscillator
  • PTY 28.38
  • WVE 23.26

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: